Northeast Pharmaceutical Unit Wins Chinese Approval for Empagliflozin Tablets
Northeast Pharmaceutical announced on September 15, 2026, that its wholly owned subsidiary, Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co. , Ltd. , has received a Drug Registration Certificate for empagliflozin tablets issued by China's National Medical Products Administration.
Empagliflozin tablets are used to treat type 2 diabetes, heart failure, and chronic kidney disease.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 40/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.